DK0542949T3 - Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner - Google Patents

Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner

Info

Publication number
DK0542949T3
DK0542949T3 DK92910019T DK92910019T DK0542949T3 DK 0542949 T3 DK0542949 T3 DK 0542949T3 DK 92910019 T DK92910019 T DK 92910019T DK 92910019 T DK92910019 T DK 92910019T DK 0542949 T3 DK0542949 T3 DK 0542949T3
Authority
DK
Denmark
Prior art keywords
hepatitis
havs
relates
virus
vaccines
Prior art date
Application number
DK92910019T
Other languages
Danish (da)
English (en)
Inventor
Ck Reinhard Gl
Stefan Brantschen
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Application granted granted Critical
Publication of DK0542949T3 publication Critical patent/DK0542949T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009Picornaviridae, e.g. hepatitis A virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK92910019T 1991-05-08 1992-05-08 Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner DK0542949T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91107526 1991-05-08
PCT/EP1992/001013 WO1992019268A1 (en) 1991-05-08 1992-05-08 New hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines

Publications (1)

Publication Number Publication Date
DK0542949T3 true DK0542949T3 (da) 1998-12-07

Family

ID=8206711

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92910019T DK0542949T3 (da) 1991-05-08 1992-05-08 Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner

Country Status (10)

Country Link
EP (1) EP0542949B1 (ja)
JP (1) JP3527238B2 (ja)
AT (1) ATE163548T1 (ja)
AU (1) AU662528B2 (ja)
CA (1) CA2086832C (ja)
DE (2) DE542949T1 (ja)
DK (1) DK0542949T3 (ja)
ES (1) ES2056780T3 (ja)
GR (2) GR930300089T1 (ja)
WO (1) WO1992019268A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205536T1 (de) * 1992-09-18 2001-09-15 Smithkline Beecham Biolog Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
PL1802746T3 (pl) 2004-10-27 2011-10-31 Crucell Switzerland Ag Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B
CN116514965B (zh) * 2023-06-15 2023-11-10 上海精翰生物科技有限公司 甲型肝炎病毒抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
CA1164799A (en) * 1979-09-04 1984-04-03 Paula A. Giesa Cell culture of hepatitis a virus

Also Published As

Publication number Publication date
AU662528B2 (en) 1995-09-07
CA2086832C (en) 2007-05-01
GR930300089T1 (en) 1993-09-30
EP0542949A1 (en) 1993-05-26
ATE163548T1 (de) 1998-03-15
GR3026612T3 (en) 1998-07-31
ES2056780T3 (es) 1998-08-16
CA2086832A1 (en) 1992-11-09
ES2056780T1 (es) 1994-10-16
AU1743692A (en) 1992-12-21
DE69224590T2 (de) 1998-10-15
DE542949T1 (de) 1993-09-02
JP3527238B2 (ja) 2004-05-17
EP0542949B1 (en) 1998-03-04
JPH06500238A (ja) 1994-01-13
DE69224590D1 (de) 1998-04-09
WO1992019268A1 (en) 1992-11-12

Similar Documents

Publication Publication Date Title
DK0589004T3 (da) Fremgangsmåde til bestemmelse af peptider, som hører til immunologisk vigtige epitoper af HCV
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
EP0677533A3 (en) Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
DK158743C (da) Fremgangsmaade til fremstilling af et levende, svaekket hepatitis a virus og diagnostisk praeparat opnaaet ved fremgangsmaaden
NO975434L (no) Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
DK0649537T4 (da) Immunoassays til anti-HCV-antistoffer, ved anvendelse af antigener med konformationelle epitoper
FI942369A (fi) Hepatitis-C-virustesti
HUP9903770A2 (hu) Eljárások és készítmények többepitópos antigének konformációjának megváltoztatására immunválasz kiváltása céljából
WO1993001210A3 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
Weiland et al. Development of monoclonal neutralizing antibodies against bovine viral diarrhea virus after pretreatment of mice with normal bovine cells and cyclophosphamide
DK0542949T3 (da) Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner
DK0701612T3 (da) Immunogent præparat af OspC-antigenvacciner til forebyggelse og behandling af Lyme sygdom og rekombinantmetode til fremsti
DK1002092T3 (da) Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf
DE69224134D1 (de) Monoklonale Antikörper gegen Hepatitis-C-Virus
EP0967223A3 (de) Hepatitis C Virus Peptidantigene und Verfahren zur Bestimung von Hepatitis C Virus (HCV)
DK0569537T3 (da) Monoklonale antistoffer mod formodede HCV-kapperegioner og fremgangsmåder til anvendelse deraf
SE8601695L (sv) Fast-fasanalysmetod
NO953749L (no) Hepatitt B-escapemutantspesifikke bindingsmolekyler
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
DK0599913T3 (da) Monoklonale antistoffer mod formodet hepatitis C-virus NS5-proteiner og anvendelsesmetoder af samme
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
Brantschen Hepatitis A virus strain, method for the isolation of new hepatitis A virus strains and hepatitis A vaccines
DK0565548T3 (da) Tofasesystem til fremstilling og præsentation af fremmede antigener i levende hybridvacciner
EA200200730A1 (ru) Способ идентификации веществ, имитирующих эпитопы млекопитающих
BR0204612C1 (pt) anticorpos monoclonais antinúcleo de hcv